Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
133 hedge funds and large institutions have $609M invested in Paratek Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 48 increasing their positions, 33 reducing their positions, and 20 closing their positions.
70% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 20
64% more call options, than puts
Call options by funds: $8.47M | Put options by funds: $5.15M
45% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 33
12% more funds holding
Funds holding: 119 → 133 (+14)
8% more capital invested
Capital invested by funds: $564M → $609M (+$45.4M)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$17.6M |
| 2 |
ECP
Empyrean Capital Partners
Los Angeles,
California
|
+$15.6M |
| 3 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
+$7.97M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$7.33M |
| 5 |
Millennium Management
New York
|
+$7.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$12.8M |
| 2 |
IVM
InterWest Venture Management
San Francisco,
California
|
-$12.3M |
| 3 |
AC
Aisling Capital
New York
|
-$11.6M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8.44M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.36M |
PRTK Hedge Fund Activity: Q3 2017 in Review
133 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q3 2017, worth a combined $609M — up 8.1% from $564M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new PRTK positions and 20 closed out — a net gain of 14 holders — while 48 added to existing stakes and 33 trimmed.
The largest buyer was Alyeska Investment Group, adding an estimated $17.6M. The largest seller was Tekla Capital Management, exiting entirely with an estimated $12.8M sold.
- 133 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q3 2017, up from 119 in Q2 2017.
- Funds reported $609M of Paratek Pharmaceuticals, Inc. stock for Q3 2017, up 8.1% quarter-over-quarter.
- 34 funds opened new Paratek Pharmaceuticals, Inc. positions in Q3 2017 and 20 closed out, a net change of +14 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q3 2017 was Alyeska Investment Group, an estimated $17.6M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q3 2017 was Tekla Capital Management, an estimated $12.8M sold.
Based on aggregated 13F filings for Q3 2017.